向传平 周伟 邹宏林 谭海波 周翠萍

[摘要] 目的 对利拉鲁肽与胰岛素强化治疗对肥胖2型糖尿病患者的效果进行分析和研究。方法 选择2017年12月—2018年6月该院收治的的90例肥胖2型糖尿病患者作为研究对象，随机将其划分为对照组和观察组，每组各有45例患者。采用胰岛素对对照组患者进行治疗，在此基础上采用利拉鲁肽治疗观察组，对两组患者的治疗效果进行分析和比较。结果 两组患者治疗前血糖情况相比差异无统计学意义（P>0.05）。观察组治疗后的血糖情况均明显低于对照组，两组患者相比差异有统计学意义（P<0.05）。两组患者的不良反应发生率相比差异无统计学意义（P>0.05）。结论 在肥胖2型糖尿病患者的临床治疗中采用利拉鲁肽与胰岛素具有很好的效果，而且安全性较高。

[关键词] 肥胖型;2型糖尿病;利拉鲁肽;胰岛素

[中图分类号] R587.1          [文献标识码] A          [文章编号] 1672-4062（2019）09（b）-0189-02

[Abstract] Objective To analyze and study the effect of intensive treatment with liraglutide and insulin on obese patients with type 2 diabetes. Methods A total of 90 obese patients with type 2 diabetes admitted to our hospital from December 2017 to June 2018 were enrolled in the study. They were randomly divided into control group and observation group， with 45 patients in each group. The patients in the control group were treated with insulin. On the basis of this， the treatment group was treated with liraglutide， and the therapeutic effects of the two groups were analyzed and compared. Results There was no significant difference in pre-treatment blood glucose between the two groups（P>0.05）. The blood glucose level of the observation group was significantly lower than that of the control group， and the difference between the two groups was significant（P<0.05）. There was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）. Conclusion The use of liraglutide and insulin in the clinical treatment of obese patients with type 2 diabetes has a good effect and is safe.

[Key words] Obesity; Type 2 diabetes; Liraglutide; Insulin

在糖尿病患者中大多數都是2型糖尿病，其所占比例高于90%，在人们生活水平越来越高的今天，2型糖尿病中出现了越来越多的肥胖患者，肥胖在高血压、脂代谢紊乱、动脉粥样硬化以及2型糖尿病中都属于高度危险因素，与非肥胖患者相比，肥胖2型糖尿病患者具有明显更强的胰岛素抵抗，而且在进行血糖控制的时候难度更大，所以如何有效治疗肥胖2型糖尿病患者受到了临床上的普遍关注[1]。基于此，该文回顾性分析了2017年12月—2018年6月该院收治的的90例肥胖2型糖尿病患者的临床资料，对利拉鲁肽与胰岛素强化治疗对肥胖2型糖尿病患者的效果进行分析和研究，现报道如下。